share_log

Brookline Capital Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $16

Brookline Capital Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $16

Brookline Capital以買入評級啟動Oncternal治療藥物的覆蓋範圍，宣佈目標價為16美元
Benzinga Real-time News ·  2021/03/30 22:05

Brookline Capital analyst Kumaraguru Raja initiates coverage on Oncternal Therapeutics (NASDAQ:ONCT) with a Buy rating and announces Price Target of $16.

Brookline Capital分析師Kumaraguru Raja發起Oncternal Treeutics(納斯達克：ONCT)，買入評級，並宣佈目標價為16美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論